Drug Profile
Research programme: cancer metabolism modulators - Dynamix
Alternative Names: DNX-03000; DNX-03024; DNX-06000; DNX-3000; DNX-6000; PKM2 activators - DynamixLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dynamix Pharmaceuticals
- Class Small molecules
- Mechanism of Action Glycolysis modulators; Pyruvate kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (PO)
- 15 Jun 2011 Research programme: cancer metabolism enzyme modulators - Dynamix is available for licensing as of 15 Jun 2011. http://www.dynxp.com
- 05 Apr 2011 Preclinical trials in Solid tumours in Israel (PO)